Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 4Completed 2Terminated 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 5Lymphoid 3Gastrointestinal 3Thoracic 2Head & Neck 2Dermatologic 2Other hematologic neoplasm 1Myeloid 1Gynecologic 1Genitourinary 1CNS 1

Conditions

Ovarian Neoplasms 368Uterine Cervical Neoplasms 144Carcinoma, Ovarian Epithelial 108Fallopian Tube Neoplasms 105Endometrial Neoplasms 99Breast Neoplasms 82Carcinoma, Non-Small-Cell Lung 70Neoplasms 55Stomach Neoplasms 49Melanoma 44Colorectal Neoplasms 44Neoplasm Metastasis 40Pancreatic Neoplasms 37Carcinoma, Renal Cell 36Triple Negative Breast Neoplasms 33Recurrence 31Squamous Cell Carcinoma of Head and Neck 28Lung Neoplasms 28Uterine Neoplasms 25Sarcoma 25Urinary Bladder Neoplasms 24Peritoneal Neoplasms 24Uterine Cervical Dysplasia 23Prostatic Neoplasms 23Colonic Neoplasms 23Esophageal Neoplasms 22Head and Neck Neoplasms 21Carcinoma, Transitional Cell 18Testicular Neoplasms 16Small Cell Lung Carcinoma 16

Interventions

olaparib 1CYH33 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Hereditary Sensory and Autonomic Neuropathies × Gynecologic × Clear all
NCT04586335 2024-03-21

Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.

Haihe Biopharma Co., Ltd.

Phase 1 Terminated
24 enrolled
BreastGenitourinaryGynecologic

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡